vs
Side-by-side financial comparison of Fortive (FTV) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $1.0B, roughly 1.0× Fortive). Hologic runs the higher net margin — 17.1% vs 5.4%, a 11.7% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -33.1%). Hologic produced more free cash flow last quarter ($215.2M vs $153.1M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -19.5%).
Fortive Corporation is an American industrial technology conglomerate company headquartered in Everett, Washington. The company specializes in providing essential technologies for connected workflow solutions; designing, developing, manufacturing and distributing professional and engineered products, software and services. Their products and services are split into three strategic segments; Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. As of Decem...
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
FTV vs HOLX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.0B |
| Net Profit | $55.0M | $179.1M |
| Gross Margin | 63.2% | 56.0% |
| Operating Margin | 15.5% | 22.6% |
| Net Margin | 5.4% | 17.1% |
| Revenue YoY | -33.1% | 2.5% |
| Net Profit YoY | -75.2% | -10.9% |
| EPS (diluted) | $0.16 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.5B | $1.0B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.5B | $988.0M | ||
| Q2 24 | $1.6B | $1.0B | ||
| Q1 24 | $1.5B | $1.0B |
| Q4 25 | — | $179.1M | ||
| Q3 25 | $55.0M | $187.2M | ||
| Q2 25 | $166.6M | $194.9M | ||
| Q1 25 | $171.9M | $-17.4M | ||
| Q4 24 | $208.8M | $201.0M | ||
| Q3 24 | $221.6M | $178.6M | ||
| Q2 24 | $195.1M | $194.5M | ||
| Q1 24 | $207.4M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | 63.2% | 55.6% | ||
| Q2 25 | 59.0% | 56.3% | ||
| Q1 25 | 59.8% | 37.5% | ||
| Q4 24 | 60.3% | 56.8% | ||
| Q3 24 | 60.0% | 56.4% | ||
| Q2 24 | 59.8% | 55.4% | ||
| Q1 24 | 59.3% | 53.3% |
| Q4 25 | — | 22.6% | ||
| Q3 25 | 15.5% | 22.6% | ||
| Q2 25 | 14.6% | 24.9% | ||
| Q1 25 | 15.8% | -0.7% | ||
| Q4 24 | 19.0% | 22.5% | ||
| Q3 24 | 19.3% | 23.3% | ||
| Q2 24 | 19.4% | 24.1% | ||
| Q1 24 | 19.8% | 20.7% |
| Q4 25 | — | 17.1% | ||
| Q3 25 | 5.4% | 17.8% | ||
| Q2 25 | 11.0% | 19.0% | ||
| Q1 25 | 11.7% | -1.7% | ||
| Q4 24 | 12.9% | 19.7% | ||
| Q3 24 | 14.4% | 18.1% | ||
| Q2 24 | 12.6% | 19.2% | ||
| Q1 24 | 13.6% | 16.7% |
| Q4 25 | — | $0.79 | ||
| Q3 25 | $0.16 | $0.84 | ||
| Q2 25 | $0.49 | $0.86 | ||
| Q1 25 | $0.50 | $-0.08 | ||
| Q4 24 | $0.60 | $0.87 | ||
| Q3 24 | $0.63 | $0.75 | ||
| Q2 24 | $0.55 | $0.82 | ||
| Q1 24 | $0.58 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.8M | $2.4B |
| Total DebtLower is stronger | $3.3B | $2.5B |
| Stockholders' EquityBook value | $6.5B | $5.2B |
| Total Assets | $11.9B | $9.2B |
| Debt / EquityLower = less leverage | 0.51× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4B | ||
| Q3 25 | $430.8M | $2.2B | ||
| Q2 25 | $1.8B | $1.9B | ||
| Q1 25 | $892.1M | $1.6B | ||
| Q4 24 | $813.3M | $2.0B | ||
| Q3 24 | $811.3M | $2.3B | ||
| Q2 24 | $644.1M | $2.4B | ||
| Q1 24 | $704.6M | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $3.3B | $2.5B | ||
| Q2 25 | $4.8B | $2.5B | ||
| Q1 25 | $3.9B | $2.5B | ||
| Q4 24 | $3.7B | $2.5B | ||
| Q3 24 | $3.9B | $2.5B | ||
| Q2 24 | $3.8B | $2.5B | ||
| Q1 24 | $3.9B | $2.6B |
| Q4 25 | — | $5.2B | ||
| Q3 25 | $6.5B | $5.0B | ||
| Q2 25 | $10.4B | $4.8B | ||
| Q1 25 | $10.2B | $4.6B | ||
| Q4 24 | $10.2B | $4.8B | ||
| Q3 24 | $10.6B | $5.1B | ||
| Q2 24 | $10.5B | $5.0B | ||
| Q1 24 | $10.5B | $4.8B |
| Q4 25 | — | $9.2B | ||
| Q3 25 | $11.9B | $9.0B | ||
| Q2 25 | $18.2B | $8.8B | ||
| Q1 25 | $17.1B | $8.5B | ||
| Q4 24 | $17.0B | $8.7B | ||
| Q3 24 | $17.5B | $9.2B | ||
| Q2 24 | $17.3B | $8.9B | ||
| Q1 24 | $17.5B | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | 0.51× | 0.50× | ||
| Q2 25 | 0.46× | 0.52× | ||
| Q1 25 | 0.38× | 0.55× | ||
| Q4 24 | 0.36× | 0.53× | ||
| Q3 24 | 0.37× | 0.49× | ||
| Q2 24 | 0.36× | 0.51× | ||
| Q1 24 | 0.38× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $164.4M | $229.9M |
| Free Cash FlowOCF − Capex | $153.1M | $215.2M |
| FCF MarginFCF / Revenue | 14.9% | 20.5% |
| Capex IntensityCapex / Revenue | 1.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.99× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $229.9M | ||
| Q3 25 | $164.4M | $355.1M | ||
| Q2 25 | $311.2M | $343.3M | ||
| Q1 25 | $241.7M | $169.4M | ||
| Q4 24 | $502.2M | $189.3M | ||
| Q3 24 | $459.0M | $367.0M | ||
| Q2 24 | $308.9M | $405.8M | ||
| Q1 24 | $256.7M | $292.4M |
| Q4 25 | — | $215.2M | ||
| Q3 25 | $153.1M | $341.4M | ||
| Q2 25 | $274.5M | $330.5M | ||
| Q1 25 | $215.0M | $153.9M | ||
| Q4 24 | $465.2M | $172.5M | ||
| Q3 24 | $431.2M | $350.6M | ||
| Q2 24 | $279.7M | $385.3M | ||
| Q1 24 | $230.3M | $279.6M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | 14.9% | 32.5% | ||
| Q2 25 | 18.1% | 32.3% | ||
| Q1 25 | 14.6% | 15.3% | ||
| Q4 24 | 28.7% | 16.9% | ||
| Q3 24 | 28.1% | 35.5% | ||
| Q2 24 | 18.0% | 38.1% | ||
| Q1 24 | 15.1% | 27.5% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 1.1% | 1.3% | ||
| Q2 25 | 2.4% | 1.3% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 2.3% | 1.6% | ||
| Q3 24 | 1.8% | 1.7% | ||
| Q2 24 | 1.9% | 2.0% | ||
| Q1 24 | 1.7% | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | 2.99× | 1.90× | ||
| Q2 25 | 1.87× | 1.76× | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 2.41× | 0.94× | ||
| Q3 24 | 2.07× | 2.05× | ||
| Q2 24 | 1.58× | 2.09× | ||
| Q1 24 | 1.24× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FTV
| Advanced Healthcare Solutions | $328.3M | 32% |
| Industrial Manufacturing | $287.9M | 28% |
| Energy And Infrastructure | $166.7M | 16% |
| Government | $88.0M | 9% |
| Retail | $82.7M | 8% |
| Other Direct End Markets | $79.6M | 8% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
